Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Magnetosomes as Potential Nanocarriers for Cancer Treatment
Curr Drug Deliv. 2023 Jun 19. doi: 10.2174/1567201820666230619155528. Online ahead of print.ABSTRACTMagnetotactic bacteria (MTBs) and their organelles, magnetosomes, are intriguing options that might fulfill the criteria of using bacterial magnetosomes (BMs). The ferromagnetic crystals contained in BMs can condition the magnetotaxis of MTBs, which is common in water storage facilities. This review provides an overview of the feasibility of using MTBs and BMs as nanocarriers in cancer treatment. More evidence suggests that MTBs and BMs can be used as natural nanocarriers for conventional anticancer medicines, antibodies, va...
Source: Current Drug Delivery - June 21, 2023 Category: Drugs & Pharmacology Authors: Rawan Alsharedeh Nid'a Alshraiedeh Alaa A Aljabali Murtaza M Tambuwala Source Type: research
Evaluation of a DoE based approach for comprehensive modelling of the effect of lipid nanoparticle composition on nucleic acid delivery
Biomaterials. 2023 May 15;299:122158. doi: 10.1016/j.biomaterials.2023.122158. Online ahead of print.ABSTRACTTherapeutic nucleic acids (TNAs) comprise an alternative to conventional drugs for cancer therapy. Recently, stable nucleic acid lipid particles (SNALPs) have been explored to deliver TNA efficiently and safely both in vitro and in vivo. Small interfering RNA (siRNA) and messenger RNA (mRNA) based drugs have been suggested for a wide range of pathologies, and their respective lipid nanoparticle (LNP) formulations have been optimised using a Design of Experiments (DoE) approach. However, it is uncertain as to whether...
Source: Biomaterials - May 27, 2023 Category: Materials Science Authors: Yue Qin Adam A Walters Nadia Rouatbi Julie Tzu-Wen Wang Hend Mohamed Abdel-Bar Khuloud T Al-Jamal Source Type: research
Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk
Human papillomavirus (HPV), a common sexually transmitted virus infecting mucosal or cutaneous stratified epithelia, is implicated in the rising of associated cancers worldwide. While HPV infection can be cleared by an adequate immune response, immunocompromised individuals can develop persistent, treatment-refractory, and progressive disease. Primary immunodeficiencies (PIDs) associated with HPV-related disease include inborn errors of GATA, EVER1/2, and CXCR4 mutations, resulting in defective cellular function. People living with secondary immunodeficiency (e.g. solid-organ transplants recipients of immunosuppression) an...
Source: Frontiers in Immunology - March 7, 2023 Category: Allergy & Immunology Source Type: research
Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
Source: Pharmaceutical Research - December 7, 2022 Category: Drugs & Pharmacology Source Type: research
Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery
J Control Release. 2022 Nov 10:S0168-3659(22)00739-8. doi: 10.1016/j.jconrel.2022.10.061. Online ahead of print.ABSTRACTWith the rapid development of biopharmaceuticals and the outbreak of COVID-19, the world has ushered in a frenzy to develop gene therapy. Therefore, therapeutic genes have received enormous attention. However, due to the extreme instability and low intracellular gene expression of naked genes, specific vectors are required. Viral vectors are widely used attributed to their high transfection efficiency. However, due to the safety concerns of viral vectors, nanotechnology-based non-viral vectors have attrac...
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Hezhi Wang Lu Qin Xin Zhang Jian Guan Shirui Mao Source Type: research
Targeting K-Ras Mutations Show Promise Towards Ending Ras's "Undruggable" Era
Protein Pept Lett. 2022 Oct 3. doi: 10.2174/0929866529666221003124202. Online ahead of print.ABSTRACTIt has almost been 40 years since the Ras proteins were discovered as the first human oncogenes. They remain among the most important genes for regulating mammalian cell growth and are involved in more than a quarter of human cancers. Out of 167 members of the Ras superfamily, K-Ras mutations are the most abundant in human cancers. Particularly, the K-Ras G12C mutations are known to be involved in pancreatic, colon and lung cancers as well as leukemias. Though progress has been made, approaches that target Ras proteins for ...
Source: Protein and Peptide Letters - October 6, 2022 Category: Biochemistry Authors: Paul D Adams D Jamali Muhoza Source Type: research
